[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye-symptoms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627634","phase-4-comparison-of-ocular-lubricants-in-people-with-symptoms-of-dry-eye-100627634",false,"NCT07451184","Comparison of Ocular Lubricants in People With Symptoms of Dry Eye","Symptomology Changes With Systane PRO PF Versus Thealoz Duo","SPHINX","Inclusion Criteria:\n\n1. Are at least 18 years of age and have full legal capacity to volunteer;\n2. Have understood and signed an institutional review board (IRB)\u002F independent ethics committee (IEC) approved informed consent form;\n3. Are willing and able to attend all study visits as required per protocol;\n4. Are willing to discontinue use of all habitual artificial tear supplements and use only the study drops as directed for the entire study duration;\n5. Have dry eye symptomatology as per Tear Film \\& Ocular Surface Society Dry Eye WorkShop (TFOS DEWS) II definition:\n\n   * Have an Ocular Surface Disease Index (OSDI) score ≥13;\n6. Have an absence of active\\* anterior segment disease;\n7. Have not worn contact lenses for the previous 14 days before screening, and are willing to not wear contact lenses for the duration of the study;\n8. Are correctable to a visual acuity of +0.20 LogMAR or better (in at least one eye) with refraction results.\n\nExclusion Criteria:\n\n1. Have taken part in an interventional clinical study within the previous 14 days before screening;\n2. Are participating in any concurrent ocular or interventional clinical trial;\n3. Have any active\\* ocular inflammation, infection, or are using ocular topical treatment (other than dry eye drops);\n4. Started any systemic medication known to cause dry eye (e.g., anti-histamine, antidepressants, benzodiazepines, etc.) within 30 days before screening. Stable dosing for \\>30 days before screening is allowed, but changes (including commencing new) of dosing of such medication within the study period would lead to early exit from the study;\n5. Had any ocular injury or surgery within the 1 year prior to screening, nor have ocular surgery planned\u002F anticipated;\n6. Have biomicroscopy signs of grade 3 or more (Efron scale);\n7. Have known sensitivity to the diagnostic pharmaceuticals or to any ingredients in the study products;\n8. Are pregnant, lactating or planning a pregnancy at the time of enrolment;\n9. Are a member of the Centre for Ocular Research \\& Education directly involved in this study (on the delegation log);\n10. Are an employee of Alcon.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Ocular dryness and discomfort are symptoms commonly associated with dry eye. Lubricating eye drops, also called artificial tears, are often used to moisten the eye and provide relief from these symptoms. There are currently several types of lubricating eye drops available, differing in their ingredients, consistency, and recommended frequency of application. The aim of this study is to compare the effectiveness of two lubricating eye drops that differ in their ingredients and recommended frequency of application. The goal is to see whether they perform the same or if one of them provides better relief for people with dry eye symptoms. One of the eye drops is commercially available in Canada, the other one is not commercially available in Canada and therefore considered an investigational eye drop. This eye drop is available in the United States of America. In this study, participants will use one drop twice per day and the other drop four times per day. Each product will be used for 4 weeks and all participants will use both products (one after the other). There will be a 2-week period of no drops between the two study products. Before starting each drop and after 4 weeks of drop use, we will assess the eyes of the participants and ask them how their eyes feel. Participants will also be asked to answer a series of questions regarding the drops. Participants will encounter procedures that they normally experience in an eye care setting. The results will help the funding company to better understand the performance of the products used in this study. It may also help eyecare practitioners in managing their patients with dry eye symptoms. The hypothesis is that the drop used twice a day will be non-inferior to the drop used 4 times per day for the change in dry eye symptoms (assessed with the Ocular Surface Disease Index questionnaire) after 4 weeks of use.",[27],"Dry Eye Symptoms","RECRUITING","2026-04-23",{"date":31,"type":32},"2026-04-28","ACTUAL",{"date":34,"type":32},"2026-02-23",{"date":36,"type":21},"2027-05-23",{"name":38,"class":39},"University of Waterloo","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100614417","safety-and-efficacy-of-kelulut-honey-eyedrops-in-dry-eye-disease-100614417","NCT07279324","Safety and Efficacy of Kelulut Honey Eyedrops in Dry Eye Disease","Pilot Study on the Safety and Efficacy of Kelulut Honey Eyedrops for Dry Eye Disease","Inclusion Criteria:\n\n1. Age 18-50 years at the time of consent.\n2. Clinical diagnosis of dry eye disease in at least one eye, based on symptoms and clinical signs (Symptomatic dry eye, defined as an OSDI score ≥ 13; objective evidence of tear film instability, such as TBUT \\\u003C 10 seconds in at least one eye)\n3. Participants may be Treatment-naïve, OR on stable dry eye treatment for at least 2 weeks before enrollment.\n4. Willing to use Kelulut honey eyedrops three times daily for 1 month as instructed.\n5. Able and willing to attend all study visits (Baseline, Week 2, Week 4).\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to honey, bee products, or any component of the study formulations.\n2. Active ocular infection or inflammation (e.g., infectious conjunctivitis, keratitis, uveitis).\n3. Severe allergic conjunctivitis or other ocular surface diseases\n4. Significant meibomian gland dysfunction or blepharitis\n5. Ocular surgery or laser procedures within the past 6 months.\n6. Use of topical ocular medications other than lubricants within the past 30 days\n7. Contact lens wear within 1 week prior to baseline or expected during the study.\n8. Punctal plugs or other lacrimal procedures within the last 3 months.\n9. Systemic diseases that significantly affect the ocular surface and are unstable or uncontrolled (e.g., uncontrolled Sjögren's, uncontrolled rheumatoid arthritis, uncontrolled diabetes).\n10. Participation in another clinical trial or receipt of an investigational product within the past 30 days.\n11. Pregnant or breastfeeding women, or those planning pregnancy during the study.","50 Years",{"count":50,"type":21},45,[52],"NA","The goal of this clinical trial is to learn whether Kelulut honey eyedrops are safe and helpful in treating dry eye disease in adults. It will also learn about any side effects that may occur with the use of Kelulut honey eyedrops.\n\nThis Kelulut honey eyedrops are sterile ophthalmic solutions formulated with honey derived from stingless bees (Trigona spp.) at concentrations of 12.5% 25% and 50%. The eyedrop formulations are prepared according to a standardized laboratory protocol to ensure sterility, stability, and suitability for ocular use. Full formulation details are proprietary but can be provided to the ethics committee or regulatory authorities upon request.\n\nThe main questions this clinical trial aims to answer are:\n\n1. Does Kelulut honey improve tear film stability and dry eye symptoms?\n2. Are Kelulut honey eyedrops safe and well tolerated on the ocular surface?\n\nResearchers will compare different concentrations of Kelulut honey eyedrops to determine which concentration provides the best balance of safety and clinical benefit.\n\nParticipants will:\n\n1. Use Kelulut honey eyedrops (12.5%, 25%, or 50%) three times daily for 1 month, in addition to continuing their usual dry eye treatments.\n2. Attend scheduled follow-up visits (on week 2 and week 4) for eye examinations and dry eye assessments (e.g., TBUT, ocular surface staining, Schirmer test, and OSDI).\n3. Report any changes in symptoms or any discomfort, including stinging, redness, irritation, or other adverse effects experienced during the study.",[55,56,27],"Dry Eye Disease (DED)","Dry Eye Syndrome (DES)","NOT_YET_RECRUITING","2025-11-30",{"date":60,"type":32},"2025-12-12",{"date":62,"type":21},"2026-04-01",{"date":64,"type":21},"2026-10-30",{"name":66,"class":39},"Universiti Sains Malaysia",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100613988","kelulut-honey-for-allergic-conjunctivitis-and-dry-eye-symptoms-100613988","NCT07273747","Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms","A Randomized Controlled Trial on the Effects of Oral Kelulut Honey Supplementation on Conjunctival Goblet Cell Density, Tear Film Stability, Dry Eye Disease Symptoms and Vision-Related Function in Patients With Allergic Conjunctivitis","Inclusion Criteria:\n\ni. Age between 18-40 years old ii. Confirmed diagnosis of allergic conjunctivits iii. Ocular surface disease index (OSDI) score \\> 12 iv. Compliance to conventional allergic conjunctivitis treatment\n\nExclusion Criteria:\n\ni. Any corneal or ocular surface pathology ii. Known diabetes mellitus or impaired glucose test iii. Ocular surface disease due to trachoma or other inflammatory conditions iv. Consume anti-inflammatory medications such as steroids, NSAIDS, oral doxycycline v. Concurrent use of other supplements or alternative therapies such as royal jelly, Manuka honey eye drop or omega-3 fatty acid vi. Using preservative-containing topical eye drops for ocular problems other than AC, such as anti-glaucoma medication vii. History of ocular trauma\u002Fsurgery or refractive surgery within last 3 years viii. Wearing contact lens in the last 3 months ix. Underlying inflammatory\u002F systemic disease and connective tissue diseases x. Recent conjunctivitis in the last 3 months xi. Patients on immunosuppressant","40 Years",{"count":76,"type":21},72,[52],"The goal of this clinical trial is to learn if oral Kelulut honey works to improve eye symptoms in adults with allergic conjunctivitis. It will also look at how safe Kelulut honey is when taken as a daily supplement.\n\nThe main questions it aims to answer are:\n\n1. Does oral Kelulut honey reduce itchy, red, watery eyes and dry eye symptoms in people with allergic conjunctivitis?\n2. Does oral Kelulut honey improve tear film stability and the health of conjunctival goblet cells (special cells on the eye surface that help keep the eye moist)?\n3. What side effects or medical problems do participants have when taking Kelulut honey?\n\nResearchers will compare oral Kelulut honey to a honey-flavoured placebo syrup (a look-alike drink that does not contain Kelulut honey) to see if Kelulut honey is more effective than placebo for treating eye symptoms in allergic conjunctivitis.\n\nParticipants will:\n\n1. Take either oral Kelulut honey or a honey-flavoured placebo syrup every day for 1 month\n2. Continue their usual treatment for allergic conjunctivitis and dry eye disease as prescribed by their eye doctor\n3. Attend clinic visits for eye check-ups, including tests of tear film stability, dry eye symptoms, and eye surface health\n4. Answer questionnaires about their eye symptoms and how these affect their daily activities and vision-related quality of life\n\nParticipation is voluntary, and participants may stop taking part in the study at any time. Data collected up to the time they withdraw may still be used for research, but their routine medical care will not be affected",[27,80],"Allergic Conjunctivitis of Both Eyes","2025-11-28",{"date":83,"type":32},"2025-12-09",{"date":85,"type":32},"2025-09-17",{"date":87,"type":21},"2026-09",{"name":66,"class":39}]